Genetic basis of copper-tolerance in Australian Pseudomonas syringae pv. tomato

The genetic basis of copper-tolerance in Australian Pseudomonas syringae pv. tomato (Pst) was investigated through PCR assays and genome analysis. Seven PCR assays were tested targeting copper metabolising (cop) genes, this included previously published assays as well as three new assays. These assays varied in their ability to detect cop genes in copper tolerant isolates and no one set of primers tested amplified all isolates, however, there is potential for these to be developed further for diagnostic purposes. The genomes of three copper tolerant isolates were sequenced using the Illumina platform. The genome assemblies of these isolates identified putative Cop and CopR/CusS operons homologous to those previously characterised in Pst as mediators of copper-tolerance. Analysis also suggests that the Cop and CopR/CusS operons may be located on either plasmid or chromosomal DNA, depending on the isolate studied. An additional CopAB complex was identified in the genomic assemblies of the three Pst isolates, and was homologous to chromosomal CopA and CopB in a copper sensitive Pst reference genome. Other potential copper metabolising genes were also identified. This is the first genomic analysis of copper tolerant Pst isolated outside of America, with PCR assays and genetic analysis revealing that the genetics of copper-tolerance in Pst is complex and diverse

Additional file 2: Figure S2. of Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision

Endoscopy pathway. (DOC 80 kb

Additional file 3: Table S1. of Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision

Analysis of outliers. (DOCX 20.9 kb

Additional file 1: Figure S1. of Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision

ERCP pathway. (DOCM 39 kb

Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry

Objective: Heart failure with preserved ejection fraction (HFpEF) is a common heterogeneous syndrome that remains imprecisely defined and consequently has limited treatment options and poor outcomes. Methods: The UK Heart Failure with Preserved Ejection Fraction Registry (UK HFpEF) is a prospective data-enabled cohort and platform study. The study will develop a large, highly characterised cohort of patients with HFpEF. A biobank will be established. Deep clinical phenotyping, imaging, multiomics and centrally held national electronic health record data will be integrated at scale, in order to reclassify HFpEF into distinct subgroups, improve understanding of disease mechanisms and identify new biological pathways and molecular targets. Together, these will form the basis for developing diagnostics and targeted therapeutics specific to subgroups. It will be a platform for more effective and efficient trials, focusing on subgroups in whom targeted interventions are expected to be effective, with consent in place to facilitate rapid recruitment, and linkage for follow-up. Patients with a diagnosis of HFpEF made by a heart failure specialist, who have had natriuretic peptide levels measured and a left ventricular ejection fraction >40% are eligible. Patients with an ejection fraction between 40% and 49% will be limited to no more than 25% of the cohort. Conclusions: UK HFpEF will develop a rich, multimodal data resource to enable the identification of disease endotypes and develop more effective diagnostic strategies, precise risk stratification and targeted therapeutics. Trial registration number: NCT05441839.</p